The mechanisms of platinum resistance are multifactorial and may involve any of the following: alteration of multiple molecular pathways including mutation and silencing of tumor suppressor genes, activation of oncogenes, epigenetic modifications, dysregulation of cell survival pathways (PI3K/Akt) and anti-apoptotic signalling pathways (Bcl-2, Bcl-xl, p53), epithelial to mesenchymal transition (EMT), dysregulation in drug uptake and efflux, tumor microenvironment, increased DNA damage repair and the upregulation of gelsolin expression and function [6–13]. Here, TP53 is linked to neoplasm.